Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (6,579)	$ (10,235)	$ (17,909)
Adjustments to reconcile net loss to net cash used in operating activities:
Inventory write-off	7	196	435
Depreciation and amortization	197	843	835
Provision for doubtful accounts	(48)	0	110
Perpetual licensing revenue from a related party	0	(8,000)	(5,000)
Stock-based compensation	513	2,614	1,525
Interest cost	187	107	760
Gain on promissory note conversion	0	(1,222)	0
Gain on sale of equipment	(40)	0	0
Loss in joint venture	1,468	2,516	6,836
Changes in fair value of promissory note	699	(605)	(927)
Changes in operating assets and liabilities:
Accounts receivable	(690)	(940)	(245)
Inventory	(603)	(4,303)	(1,072)
Prepaid expenses and other current assets	108	(518)	(283)
Other assets	17	11	206
Accounts payable and accrued expenses	(195)	198	(116)
Deferred revenue	(169)	(159)	674
Accrued payroll and benefits	195	(239)	56
Net cash used in operating activities	(4,933)	(19,736)	(14,115)
Cash flows from investing activities:
Purchases of property and equipment	(164)	(595)	(58)
Investment in joint venture	(968)	(4,526)	(7,348)
Net cash used in investing activities	(1,132)	(5,121)	(7,406)
Cash flows from financing activities:
Proceeds from sale of equipment	4	0	0
Proceeds from stock option exercise	2	221	32
Proceeds from issuance of common stock	1,000	50,900	36,520
Cost associated with issuance of common stock	(50)	(1,127)	(3,133)
Proceeds from exercise of warrants	0	272	0
Payment for repurchase of common stock	0	0	(211)
Payment for taxes related to net share settlement of restricted stock units	0	(768)	0
Loan repayment	0	0	(50)
Net cash provided by financing activities	956	49,498	33,158
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	(85)	(206)	182
Net increase (decrease) in cash, cash equivalents and restricted cash	(5,194)	24,435	11,819
Cash, cash equivalents and restricted cash at beginning of period	14,694	9,500	2,875
Cash, cash equivalents and restricted cash at end of period	9,500	33,935	14,694
Supplemental disclosures of cash flow information:
Interest expense paid	153	685	915
Supplemental non-cash investing activity:
Equipment purchases	0	250	0
Supplemental non-cash financing activity:
Issuance of shares in connection with a service contract	0	500	0
Development loan reduction related to perpetual licensing revenue	0	8,000	5,000
Conversion of promissory note	0	15,600	0
Conversion of preferred stock to common stock in connection with the Reverse Merger	0	0	85,658
Private placement offering cost	$ 0	$ 0	$ 223